BioMarin Pharmaceutical Inc. (BMRN)
Automate Your Wheel Strategy on BMRN
With Tiblio's Option Bot, you can configure your own wheel strategy including BMRN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMRN
- Rev/Share 15.3836
- Book/Share 30.3375
- PB 1.9069
- Debt/Equity 0.1028
- CurrentRatio 5.5203
- ROIC 0.0718
- MktCap 11094241600.0
- FreeCF/Share 3.2476
- PFCF 17.8887
- PE 21.0876
- Debt/Assets 0.0833
- DivYield 0
- ROE 0.0946
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | BMRN | Morgan Stanley | -- | Overweight | -- | $97 | July 3, 2025 |
| Upgrade | BMRN | Oppenheimer | Perform | Outperform | -- | $98 | Feb. 24, 2025 |
| Resumed | BMRN | Raymond James | -- | Outperform | -- | $79 | Oct. 10, 2024 |
| Upgrade | BMRN | Bernstein | Market Perform | Outperform | $94 | $110 | Aug. 20, 2024 |
News
5 Historically Cheap Growth Stocks to Buy With Confidence in the Wake of the Nasdaq Correction
Published: March 27, 2025 by: The Motley Fool
Sentiment: Positive
Every so often, Wall Street sends a not-so-subtle reminder to investors that stocks can move in both directions.
Read More
BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue?
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
Read More
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
New data also to be presented for PALYNZIQ® (pegvaliaise-pqpz), reinforcing its value in sustaining blood Phe level reduction and improving health-related quality of life for adults with phenylketonuria SAN RAFAEL, Calif. , March 20, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive new data from studies of VOXZOGO ® (vosoritide) in children with achondroplasia and in ongoing clinical trials investigating other skeletal conditions, as well as PALYNZIQ ® (pegvaliase-pqpz) in adults with phenylketonuria (PKU).
Read More
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Buy These 5 Top-Ranked Stocks to Play Likely Earnings Beat
Published: March 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Top-ranked stocks Doximity (DOCS), Life Time Group Holdings (LTH), Adtalem Global Education (ATGE), BioMarin Pharmaceutical (BMRN) and Iridium Communications (IRDM) are likely to beat on the bottom line in their upcoming releases.
Read More
4 Discounted PEG Stocks Offering the Best Returns to Value Investors
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Here we present four discounted PEG stocks that qualify our screening criteria, TAP, BMRN, DVN and JAZZ.
Read More
Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
BOOT, STRL, DECK & BMRN's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
Read More
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
BMRN or CSLLY: Which Is the Better Value Stock Right Now?
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
SAN RAFAEL, Calif. , Feb. 25, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4, 2025, at 6:50 AM PT / 9:50 AM ET in Boston, MA.
Read More
BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Does BioMarin (BMRN) Have the Potential to Rally 40.54% as Wall Street Analysts Expect?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 40.5% in BioMarin (BMRN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ET Company Participants Traci McCarty - Head of IR Alexander Hardy - President and CEO Brian Mueller - EVP and CFO Cristin Hubbard - EVP and Chief Commercial Officer Greg Friberg - EVP and Chief Research & Development Officer Conference Call Participants Philip Nadeau - TD Cowen Jessica Fye - JPMorgan Cory Kasimov - Evercore Christopher Raymond - Piper Sandler Gena Wang - Barclays Julian Pino - Stifel Akash Tewari - Jefferies Eli Merle - UBS Kostas Biliouris - BMO Capital Markets Sadia Rahman - …
Read More
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
BioMarin: EPS Surges Past Expectations
Published: February 19, 2025 by: The Motley Fool
Sentiment: Positive
BioMarin Pharmaceutical (BMRN 1.16%), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped analysts' consensus expectations. Adjusted earnings per share (EPS) reached $0.92, significantly outperforming the anticipated $0.53.
Read More
BioMarin to Report Q4 Earnings: Here's What to Expect
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Neutral
When BMRN reports fourth-quarter earnings, investors will likely focus on the sales performance of its dwarfism drug Voxzogo.
Read More
About BioMarin Pharmaceutical Inc. (BMRN)
- IPO Date 1999-07-26
- Website https://www.biomarin.com
- Industry Biotechnology
- CEO Alexander Hardy
- Employees 3040